TLA technology & targeted complete NGS of genes and gene fusions in leukemia
Hematological cancers are genetically complex and heterogeneous diseases. TLA can be applied to analyze individual genes of interest to detect structural variation such as gene fusions and deletions. In this appnote we discuss several case studies where TLA was used to detect gene fusions with known and novel fusion partners, as well as to find the genomic breakpoints of these cancer-driving fusions.
- Cergentis' TLA technology uniquely enables targeted complete next generation sequencing of genes of interest and the detection of all single nucleotide & structural variants.
- TLA empowers the analysis of genes relevant in research, for prognosis and therapy decisions.
- Gene fusion breakpoint sequences detected in TLA analyses are highly suitable markers for minimal residual disease tests.